Optimising Shipment Mode Amid QC Delays at Biocon Limited

Abstract

Delays in quality control (QC) turnaround time (TAT) mess up the schedules for making drugs and often require last-minute changes from sea to air freight for exports. In the case of Biocon Limited's exports, this case looks at how the choice of shipping mode is affected by the risk of QC batch release, lane transit times, and costs. When QC clears too close to shipping cut-offs, the economics of sea freight are badly hurt. A lane-risk approach uses cGMP-anchored release gates, carrier sailing schedules, SKU prioritization, and contingency buffers to keep risk under control. Regulatory guidance on Good Distribution Practice (GDP) and quality systems shapes governance frameworks, data capture methods, and review schedules that make it easier to predict when batches will be released. The case lays out rules for managing portfolios that keep compliance while moving possible volumes back to sea lanes that are better for the economy and the environment. It also shows how to weigh the costs, benefits, and carbon footprints of different options. Data-driven decision-making is possible with dashboards that track QC TAT, payload usage, demurrage costs, and mode mix, with clear responsibilities for each. Recognizing assumptions and limitations. The terms used are in line with academic standards. Findings ought to be corroborated with local evidence. Consequences hinge significantly on the fidelity of implementation and the quality of data.